SCHEMBL6288871

SCHEMBL6288871

CCCC[Sn](CCCC)(CCCC)c1ccccc1C=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.41
LMNA P02545 4/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
ALDH1A1 P00352 4/20 0.39
TSHR P16473 1/20 0.39
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TRIM24 O15164 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
IAPP P10997 1/20 0.33
GAA P10253 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6400185 0.82 ALDH1A1 (0.35) ALDH1A1IAPP
SCHEMBL4816773 0.77 KDM6B (0.33) TDP1L3MBTL1
SCHEMBL2083596 0.73 TRIM24 (0.32) TDP1HTTSMN1; SMN2TRIM24TRIM33
SCHEMBL1453183 0.73 TSHR (0.36) LMNAKMT2AMEN1ALDH1A1TSHR
SCHEMBL11202895 0.72 TSHR (0.39) TDP1LMNAKMT2AMEN1BLM
SCHEMBL3227093 0.72 CYP1A2 (0.44) TDP1ALDH1A1SMN1; SMN2L3MBTL1CYP2C9
SCHEMBL31558464 0.72 SMN1; SMN2 (0.36) TDP1KMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL3848205 0.72 RECQL (0.36) KMT2AMEN1ALDH1A1TSHR
SCHEMBL7505763 0.72 SMN1; SMN2 (0.36) TDP1KMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL1839511 0.70 TSHR (0.47) TDP1LMNAKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3749653-A1 PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY The Johns Hopkins University (US) 2020-12-16 EP disclosed
WO-2019157037-A1 PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY THE JOHNS HOPKINS UNIVERSITY (US) 2019-08-15 WO disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 TDP1 1197/4885LMNA 1057/4885KMT2A 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.